www.lyciatx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $203.31MM
Lycia Therapeutics is a biotechnology company and the developer of a treatment technology, Lysosomal Targeting Chimera (LYTAC), that aims to degrade extracellular proteins with the goal of treating conditions including cancer, inflammation, and autoimmune disorders. The company has a mission to uncover use cases for the LYTAC platform using extracellular protein degradation designed to target soluble and membrane-bound proteins. Lycia Therapeutics was founded in 2019 by Dr. Carolyn Bertozzi and is headquartered in San Francisco, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/13/2024 | Series C | $106.6MM | $xx.xx | $313.67MM | Venrock Healthcare Capital Partners, Janus Henderson Investors, Marshall Wace, Franklin Templeton, Redmile Group, RTW Investments, Blue Owl Healthcare Opportunities, Invus, Eli Lilly and Company, Alexandria Venture Investments | |
Price per Share
$xx.xx
Shares Outstanding
52,211,394
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3.0
Key Investors
Venrock Healthcare Capital Partners, Janus Henderson Investors, Marshall Wace, Franklin Templeton, Redmile Group, RTW Investments, Blue Owl Healthcare Opportunities, Invus, Eli Lilly and Company, Alexandria Venture Investments
|
||||||
09/09/2021 | Series B | $71.32MM | $xx.xx | $195.08MM | Redmile Group, Versant Ventures, Cowen Healthcare Investments, Invus, RTW Investments, Eli Lilly and Company, Alexandria Venture Investments | |
Price per Share
$xx.xx
Shares Outstanding
39,597,569
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3.0
Key Investors
Redmile Group, Versant Ventures, Cowen Healthcare Investments, Invus, RTW Investments, Eli Lilly and Company, Alexandria Venture Investments
|
||||||
06/09/2020 | Series A | $25.39MM | $xx.xx | $63.48MM | Versant Ventures | |
Price per Share
$xx.xx
Shares Outstanding
25,390,410
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3.0
Key Investors
Versant Ventures
|